Prospective Genotyping For Total Hip or Knee Replacement Patients Receiving Warfarin (Coumadin)

Completed · Not applicable

Conditions studied: Venous Thromboembolism, Bleeding

In brief

Several human genes affect how medications are metabolized by the body. It is believed that knowledge of variations of these genes can help health care providers better manage an anticoagulation medicine called warfarin (Coumadin®)and as a result decrease patient problems with bleeding or the development of blood clots. This study was designed to evaluate if genetic testing can improve warfarin initiation better than usual care.

Key facts

Study ID

NCT00634907

Run by

Gwen McMillin

People needed

263

Starts

2006-09-01

Expected to finish

2008-10-01

Last updated by the study team

2017-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants were otherwise healthy adults (≥ 18 years of age) who were planning total hip or knee replacement or revision surgery at the University of Utah Hospital, and scheduled a pre-operative office visit at the University of Utah Orthopaedic Center.

You may not qualify if…

• Blood transfusion in previous two weeks
• Participant is already taking warfarin
• Pre-operative INR > 4.0
• Pre-operative bilirubin > 2.4 mg/dL
• Current active cancer diagnosis with ongoing treatment
• Concomitant medications known to exert a major interaction with warfarin such as septra, metronidazole, tramadol, amiodarone, ciprofloxacin, or cimetidine.

Where it is running

• University of Utah Health Care — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.